2014
DOI: 10.1590/0037-8682-0013-2012
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Revista da Sociedade Brasileira de Medicina Tropical http://dx.doi. org/10.1590/0037-8682-0013-2012 In vitro antimalarial activity of tigecycline against Plasmodium falciparum culture-adapted reference strains and clinical isolates from the Brazilian Amazon ABSTRACT Introduction:We evaluated the in vitro antimalarial activity of tigecycline as an alternative drug for the treatment of severe malaria. Methods: A chloroquine-sensitive Plasmodium falciparum reference strain, a chloroquine-resistant reference s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 12 publications
0
2
0
Order By: Relevance
“…Tigecycline was found to act faster against Plasmodium than any of the other antibiotics tested [13]. It was also tested against clinical isolates of P. falciparum from Gabon [11] and the Brazilian Amazon [12]. These studies demonstrate the potential of tetracycline derivatives in the development of improved anti-malarials.…”
Section: Introductionmentioning
confidence: 99%
“…Tigecycline was found to act faster against Plasmodium than any of the other antibiotics tested [13]. It was also tested against clinical isolates of P. falciparum from Gabon [11] and the Brazilian Amazon [12]. These studies demonstrate the potential of tetracycline derivatives in the development of improved anti-malarials.…”
Section: Introductionmentioning
confidence: 99%
“…All these results were confirmed in South America with the evaluation of in vitro antimalarial activity of tigecycline against culture-adapted reference strains and clinical isolates from the Brazilian Amazon [93]. However, all these in vitro studies were performed on a limited number of isolates; in vivo assays and randomized clinical trials are needed to establish the clinical applicability of tigecycline.…”
Section: Tigecyclinementioning
confidence: 82%